Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Peter Warn"'
Autor:
María Velasco-Estevez, Myrthe Mampay, Hervé Boutin, Aisling Chaney, Peter Warn, Andrew Sharp, Ellie Burgess, Emad Moeendarbary, Kumlesh K. Dev, Graham K. Sheridan
Publikováno v:
Frontiers in Aging Neuroscience, Vol 10 (2018)
A defining pathophysiological hallmark of Alzheimer’s disease (AD) is the amyloid plaque; an extracellular deposit of aggregated fibrillar Aβ1-42 peptides. Amyloid plaques are hard, brittle structures scattered throughout the hippocampus and cereb
Externí odkaz:
https://doaj.org/article/4df186f4fb1d4111b88addf82ee99b77
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25744 (2011)
BACKGROUND: Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis remains unacceptably high (70-90%) in immunocompromised patients. Amphotericin B (AMB), a polyene antibiotic with broad spectrum an
Externí odkaz:
https://doaj.org/article/dc7197c92ed84b8f9be94149dd82927b
Autor:
John O'Donnell, Peter Warn, Ann E. Jerse, Emilie Alirol, George L. Drusano, Francois Franceschi, Brian J. Werth, Brian VanScoy, Françoise Van Bambeke, Magnus Unemo, Prabha Fernandes, Kristie L. Connolly, Edward W. Hook, Lindley A. Barbee, Ursula Theuretzbacher
Publikováno v:
Clinical Microbiology and Infection, Vol. 26, no.12, p. 1630-1635 (2020)
Background Increasing multidrug resistance rates in Neisseria gonorrhoeae have raised concerns and an urgent call for new antibiotics for treatment of gonorrhoea. Several decades of subdued drug development in this field and the recent failures of tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60075dd7f663452813fef2ef24a738a0
https://doi.org/10.1016/j.cmi.2020.08.006
https://doi.org/10.1016/j.cmi.2020.08.006
Autor:
Andrew Sharp, Pia Thommes, Andreas Karas, Abdul Sattar, Nasrullah Undre, Jose Alejandro Palacios-Fabrega, Peter Warn
Publikováno v:
Journal of Antimicrobial Chemotherapy. 75:2919-2924
BackgroundDuring antifungal prophylaxis, micafungin is generally infused IV once daily over 1 h. In practice, less-frequent dosing could improve the quality of life in patients requiring long-term treatment or prophylaxis. The feasibility of this app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::700d263ae0ff995542f0fef23c77b69b
https://doi.org/10.1093/jac/dkaa243
https://doi.org/10.1093/jac/dkaa243
Publikováno v:
Medical Mycology. 58:505-513
Aspergillus spp. infections remain a global concern, with ∼30% attributable mortality of invasive aspergillosis (IA). VT-1598 is a novel fungal CYP51 inhibitor designed for exquisite selectivity versus human CYP enzymes to achieve a maximal therape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ab5eb654f773cef953eac027206e55d
https://doi.org/10.1093/mmy/myz092
https://doi.org/10.1093/mmy/myz092
Autor:
Jacob T. Rendell, Marc H. Scheetz, Lynette Cegelski, Itamar Shalit, Jiuzhi Sun, Madeline B. Chosy, Peter Warn, Paul A. Wender, Lewis F. Neville
Publikováno v:
Antimicrobial Agents and Chemotherapy
The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to Gram-negative bacteria was investigated. Its MIC toward Escherichia coli, including β-lactamase expressing Ambler classes A, B, and D, was 8 to 16 μg/ml
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d983a1bfda900947f26a6e878c26937e
https://doi.org/10.1128/aac.02416-20
https://doi.org/10.1128/aac.02416-20
Autor:
David T, Davies, Simon, Leiris, Magdalena, Zalacain, Nicolas, Sprynski, Jérôme, Castandet, Justine, Bousquet, Clarisse, Lozano, Agustina, Llanos, Laethitia, Alibaud, Srinivas, Vasa, Ramesh, Pattipati, Ravindar, Valige, Bhaskar, Kummari, Srinivasu, Pothukanuri, Cyntia, De Piano, Ian, Morrissey, Kirsty, Holden, Peter, Warn, Francesca, Marcoccia, Manuela, Benvenuti, Cecilia, Pozzi, Giusy, Tassone, Stefano, Mangani, Jean-Denis, Docquier, David, Pallin, Richard, Elliot, Marc, Lemonnier, Martin, Everett
Publikováno v:
Journal of medicinal chemistry. 63(24)
The diazabicyclooctanes (DBOs) are a class of serine β-lactamase (SBL) inhibitors that use a strained urea moiety as the warhead to react with the active serine residue in the active site of SBLs. The first in-class drug, avibactam, as well as sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e07e1cd1c01e765679dc31f45fa020e
https://pubmed.ncbi.nlm.nih.gov/33306385
https://pubmed.ncbi.nlm.nih.gov/33306385
Autor:
Cecilia Pozzi, Srinivasu Pothukanuri, Martin Everett, Nicolas Sprynski, Ramakrishna R. Juventhala, Kirsty Holden, Magdalena Zalacain, SyamKumar Godi, David T. Davies, Vengala R Ravu, Ramesh Pattipati, Raju Jallala, Peter Warn, Rajashekar Reddy Sathyap, Narasimha A Darshanoju, Stefano Mangani, Naresh Vempala, Jérôme Castandet, Praveen K Dasari, Francesca Marcoccia, Clarisse Lozano, Simon Leiris, Manuela Benvenuti, Marc Lemonnier, Srinivas Vasa, Narender Pottabathini, Somesh Sharma, Swetha Gujjewar, Jean Denis Docquier, Justine Bousquet
Publikováno v:
ACS infectious diseases. 6(9)
The clinical effectiveness of the important β-lactam class of antibiotics is under threat by the emergence of resistance, mostly due to the production of acquired serine- (SBL) and metallo-β-lactamase (MBL) enzymes. To address this resistance issue
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994107a10462ff59ea55f151a4165f94
https://pubmed.ncbi.nlm.nih.gov/32786279
https://pubmed.ncbi.nlm.nih.gov/32786279
Autor:
Rossella Cardin, Rajesh Odedra, Cedric Charrier, Matthias Machacek, Samantha Franzoni, Adam Belley, Peter Warn, Sylvie Sordello, Philipp Knechtle, Fabian Bernhard
Publikováno v:
Antimicrob Agents Chemother
Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance determinants. Enmetazobactam (formerly AAI101) is a novel ESBL inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42c7447c7ef09f062052b0336b0bcbb4
https://pubmed.ncbi.nlm.nih.gov/32253212
https://pubmed.ncbi.nlm.nih.gov/32253212
Autor:
Nicolas Sprynski, Simon Leiris, Kirsty Holden, Srinivasu Pothukanuri, Martin Everett, Agustina Llanos, Manuela Benvenuti, Srinivas Vasa, David T. Davies, Francesca Marcoccia, Richard Elliot, Magdalena Zalacain, Clarisse Lozano, Peter Warn, David Pallin, Cecilia Pozzi, Justine Bousquet, Ian Morrissey, Marc Lemonnier, Ravindar Valige, Bhaskar Kummari, G. Tassone, Jean Denis Docquier, Stefano Mangani, Jérôme Castandet, Ramesh Pattipati, Laethitia Alibaud, Cyntia De Piano
The diazabicyclooctanes (DBOs) are a class of serine β-lactamase (SBL) inhibitors that use a strained urea moiety as the warhead to react with the active serine residue in the active site of SBLs. The first in-class drug, avibactam, as well as sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d974eab718ab77cc1b0732365a12c9e0
http://hdl.handle.net/11365/1125122
http://hdl.handle.net/11365/1125122
